论文部分内容阅读
探讨新辅助化疗(紫杉醇+顺铂)不同给药方式治疗晚期宫颈癌的临床疗效及其机制.[方法]选取2016年3月至2018年3月在本院接受新辅助化疗的晚期宫颈癌患者68例,按照随机数表法分为介入组(新辅助介入动脉化疗)和静脉组(新辅助静脉化疗),每组34例.比较两组患者近期的疗效及不良反应,检测两组患者癌组织中PI3K/AKT/mTOR信号通路的相关因子磷酸化胞内磷脂酰肌醇激酶(p-PI3K)、磷酸化蛋白激酶B(p-Akt)、磷酸化雷帕霉素靶蛋白(p-mTOR)、基质金属蛋白酶2(MMP2)、血管内皮生长因子(VEGF)水平并分析其作用机制.[结果]介入组患者有效率显著高于静脉组,不良反应发生率显著低于静脉组(P<0.05);介入组患者宫颈癌组织中的p-PI3K、p-Akt、p-mTOR、MMP2、VEGF蛋白水平均显著低于静脉组(P<0.05).[结论]新辅助介入动脉化疗治疗晚期宫颈癌的近期疗效明显优于新辅助静脉化疗,且能有效地抑制宫颈癌组织细胞中的PI3K/AKT/mTOR信号通路,这可能与显著抑制其磷酸化有关.“,”ToinvestigatetheexpressionofPI3K/AKT/mTORsignalingpathwayandclinical efficacyofdifferentNeoadjuvantChemotherapyadministration (Paclitaxel+Cisplatin)foradvancedcervical cancer.[Methods]From March2016to March2018,68patientswithadvancedcervicalcancerwhoreceived neoadjuvantchemotherapyinBoaiHospitalofZhongshanCitywereselected.Accordingtotherandomtable method,theyweredividedintotheinterventionalgroup (neoadjuvantinterventionalarterialchemotherapy) andtheintravenousgroup(neoadjuvantintravenouschemotherapy),with34casesineachgroup.Thelevelsof p-PI3K,p-Akt,p-mTOR,matrixmetalloprotease2(MMP2)andvascularendothelialgrowthfactor(VEGF) werecomparedbetweenthetwogroups.Theshort-termefficacyandadversereactionswererecordedandcom-paredaswell.[Results]Theeffectiverateoftheinterventiongroup washigherthanthatoftheintravenous group,andtheincidenceofadversereactionswaslowerthanthatoftheintravenousgroup (P<0.05).The levelsofp-PI3K,p-Akt,p-mTOR,MMP2andVEGFproteinincervicalcancertissuesofinterventiongroup weresignificantlylowerthanthoseofvenousgroup(P<0.05).[Conclusion]Theshort-termefficacyofneo-adjuvantinterventionalarterialchemotherapyforadvancedcervicalcancertreatmentisbetterthanneoadjuvant intravenouschemotherapy.ItcaneffectivelyinhibitthePI3K/AKT/mTORsignalingpathwayincervicalcanc-ercells,whichmayberelatedtothesignificantinhibitionofitsphosphorylation.